Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck KGaA is putting its BTK inhibitor evobrutinib to the test in two phase 3  multiple sclerosis (MS) trials, the first drug in the class to reach that stage for the ... Merck says however that the liver enzyme increases reversed after treatment was

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation However, rival Merck KGaA has its own candidate, tepotinib, which is also being investigated in this rare form of lung cancer. ... Merck’s tepotinib also picked up fast-track status from the US regulator earlier this year, which means the race to

MSD’s Keytruda catches up in kidney cancer

MSD’s Keytruda catches up in kidney cancer president, clinical research, Merck Research Laboratories. ... added. The kidney cancer market is now becoming increasingly competitive, with Keytruda and Opdivo also facing competition from Pfizer/Merck KGaA’s Bavencio (avelumab),  which was approved

GSK hires Merck KGaA exec to lead US pharma business

GSK hires Merck KGaA exec to lead US pharma business Maya Martinez-Davis. Martinez-Davis currently serves as president of biopharma Latin America at Merck KGaA but her two previous positions were focused squarely on oncology. ... Over the past year, GSK has doubled the size of its oncology pipeline, in

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease The new data adds to a building body of evidence behind imeglimin after around a decade of development at Poxel, a spin-out of Merck KGaA formed specifically to advance the

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics